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Table 1 Arterial and venous SCFA concentrations
Concentrations
(µmol/L) Radial artery Hepatic vein Portal vein
Superior 
mesenteric vein
Inferior 
mesenteric vein
Acetate 21.8±7.6 23.6±4.8 41.4±7.8 50.4±11.3 102.7±27.2
Propionate 1.0±0.2 2.8±0.8 24.5±6.1 19.5±3.5 64.8±13.4
Butyrate 0.8±0.2 2.6±0.8 21.1±4.4 22.7±7.4 62.9±13.4
SCFA, short-chain fatty acid.
  
Distal versus proximal 
intestinal short-chain fatty acid 
release in man
Several recent studies published in Gut 
highlight the potential of prebiotics and 
short-chain fatty acids (SCFAs) to improve 
obesity and its associated metabolic 
disorders. Catry and colleagues1 demon-
strated that inulin-type fructans improve 
endothelial dysfunction, and Roager et 
al2 showed that a whole grain-rich diet 
reduced body weight and inflammation. 
Li et al3 reported that butyrate adminis-
tration reduced appetite and activated 
brown adipose tissue in mice, and Cham-
bers and colleagues4 showed that targeted 
propionate delivery to the human colon 
reduced energy intake and body weight 
gain.
In light of these important effects of 
SCFA, insight into their fate after bacterial 
production and/or intestinal absorption 
will help to improve the development of 
nutritional strategies aiming at modu-
lation of intestinal SCFA. We addressed 
this issue by assessing SCFA release in the 
proximal intestines (jejunum, ileum and 
proximal colon) versus the distal intestines 
(descending colon, sigmoid and rectum) in 
man. Blood was simultaneously sampled 
from the portal vein, hepatic vein, supe-
rior mesenteric vein (SMV; draining the 
proximal intestines), inferior mesenteric 
vein (IMV; draining the distal intes-
tines) and the radial artery in 20 patients 
undergoing upper abdominal surgery (see 
online supplementary table for patient 
characteristics).
SCFA concentrations were highest in 
the IMV and lowest in the radial artery 
(table 1). Acetate concentrations in the 
IMV and SMV were strongly correlated 
(rs=0.57, p<0.001), but propionate 
and butyrate concentrations were not 
(rs=−0.05, p>0.05; rs=0.18, p>0.05, 
respectively). Arterial acetate concentra-
tions correlated with those in the IMV 
and the portal vein (rs=0.65, p<0.01; 
rs=0.58, p<0.01, respectively) but not 
with those in the SMV (rs=0.31, p>0.05). 
Neither propionate nor butyrate concen-
trations in the different veins and the 
radial artery were correlated. Impor-
tantly, propionate and butyrate release by 
the distal intestines were ~3-fold higher 
than observed for the proximal intestines 
(propionate: −63.8±13.4 vs −18.5±3.5 
µmol/L, butyrate: −62.1±13.3 vs 
−21.8±7.4 µmol/L), and acetate was 
only released to a significant extent by the 
distal intestines (−79.9±25.5 µmol/L). 
The liver showed a significant uptake of 
all SCFA (figure 1).
The higher SCFA release by the distal 
intestines relative to the proximal intes-
tines may be explained in several ways. 
First, the mucosa of the proximal intes-
tines may metabolise a relatively larger 
fraction of SCFA.5 Second, differences in 
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Figure 1 Arteriovenous differences in SCFA concentrations across (A) proximal intestines, (B) 
distal intestines and (C) liver. Positive values indicate net SCFA uptake, while negative values 
indicate net release. Asterisks indicate statistically significant uptake or release (*p<0.05; 
**p<0.001). SCFA, short-chain fatty acid.
local SCFA production may play a role. 
Indeed, the number of bacteria is highest 
in the colon, and gut microbiota compo-
sition and activity differ substantially 
between the proximal and distal intes-
tines.6 However, SCFA concentrations are 
higher in the proximal intestinal lumen.7 
Third, apical and basolateral epithelial 
cell uptake and transport of SCFA may 
differ between intestinal segments. To 
shed light on the importance of each 
of these potential mechanisms, studies 
combining analysis of the microbiota, 
intestinal/faecal SCFA concentrations, 
mucosal SCFA uptake and SCFA release 
are warranted.
These findings have implications for 
the development of nutritional strate-
gies to modulate SCFA production and 
improve metabolic health: (1) slowly 
fermentable fibres that increase SCFA 
specifically in the distal intestines are 
expected to have higher potential for 
influencing host metabolism given the 
much higher SCFA release by the distal 
intestines, in line with the data of Cham-
bers et al4 and our recent work demon-
strating that distal but not proximal 
acetate infusion promotes fat oxidation.8 
(2) Given the substantial SCFA uptake 
by the liver, metabolic processes such as 
lipogenesis, gluconeogenesis and oxida-
tion can be influenced by modulation of 
intestinal and portal SCFA levels through 
non-digestible carbohydrates or specific 
bacteria, depending on nutritional 
status. (3) Assessing systemic acetate 
levels might represent a practical way to 
monitor the efficacy of acetogenic dietary 
fibres directed to influence overall host 
metabolism, since arterial acetate concen-
trations correlate with those in the IMV 
and the portal vein.
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